Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
2Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Owen Hughes was appointed Chief Executive Officer in January 2024 after serving as Executive Chairman and Interim CEO since January 2023. He has served as CEO of Sail Bio, Inc. since February 2022 and previously as CEO and co-founder of Cullinan Therapeutics, Inc. He brings significant leadership experience with biopharmaceutical companies and extensive expertise in corporate development and strategic planning.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Director

XOMA Royalty Corp (NASDAQ: XOMAP)

Jan 1, 2023 – Present

Independence: Not independent

Source effective: 2026-03-30 · Observed: 2026-04-25T00:22:01.125+00:00

confirmedView source

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

C4 Therapeutics, Inc.

2023-01-01 · current

Confirmed by public sourceView source

Director

XOMA Royalty Corp

2023-01-01 · current

Confirmed by public sourceView source

Director

ImageneBio, Inc.

2022-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

C4 Therapeutics, Inc.

Open C4 Therapeutics, Inc. profile →

Director at C4 Therapeutics, Inc.

2023-01-01 → End not stated

current · source reported

Observed: 2026-09-17

C4 Therapeutics, I…C4 Therapeutics, Inc.ImageneBio, Inc.ImageneBio, Inc.XOMA Royalty CorpXOMA Royalty CorpOwen Hughes

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingXOMAP DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 2 · Sec FilingCCCC DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 3 · Sec FilingIMA DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:owen-hughes
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
Jul 11, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of C4 Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of ImageneBio, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of XOMA Royalty Corp1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board role · CorroboratedBoard role: DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Audit1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Compensation1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
Jul 11, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Executive company · CorroboratedExecutive at XOMA Royalty CorporationSupported by 4 public records4 sources
Verification
Corroborated
Confidence
94%
Last reviewed
Jul 28, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 11, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Executive title · CorroboratedExecutive title: Chief Executive OfficerSupported by 3 public records3 sources
Verification
Corroborated
Confidence
94%
Last reviewed
Jul 28, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 11, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Executive title · Source reportedExecutive title: Chief Executive Officer (PEO)1 source
Verification
Source reported
Confidence
94%
Last reviewed
Jul 28, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
Jul 11, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

View all sources12 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 11, 2026

    Supports: Executive company · Executive title

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

    Supports: Executive company · Executive title

  5. https://www.sec.gov/Archives/edgar/data/791908/000119312526131866/d37986ddef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at XOMA Royalty Corp (NASDAQ: XOMAP)

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  7. https://www.sec.gov/Archives/edgar/data/1662579/000162828025020466/cccc-20250429.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at C4 Therapeutics, Inc. (NASDAQ: CCCC)

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Board role · Committee assignments

  9. https://www.sec.gov/Archives/edgar/data/1835579/000114036124022470/ny20020408x1_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 29, 2026

    Supports: Director at ImageneBio, Inc. (NASDAQ: IMA)

  10. https://www.sec.gov/Archives/edgar/data/1662579/000162828025020466/cccc-20250429.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  11. https://www.sec.gov/Archives/edgar/data/791908/000119312526131866/d37986ddef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  12. https://www.sec.gov/Archives/edgar/data/1835579/000114036124022470/ny20020408x1_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership